Chronic Obstructive Pulmonary Disease (COPD)

This information was written by Harriet Smith, Registered Dietitian, in October 2019.

We've gathered relevant information and resources on a variety of disease areas to support healthcare professionals.

This is an online CPD article. Once you've read the information below, click here to answer CPD questions and download a cerificate for your professional portfolio.

Section 1
Background Information

Chronic Obstructive Pulmonary Disease (COPD)

Chronic obstructive pulmonary disease (COPD) is a common, preventable and treatable respiratory disease.

Key Statistics1:

  • COPD is the third most common cause of death in the world

  • More than 90% of COPD deaths occur in low and middle income countries (LMICs)

  • The prevalence of COPD amongst men and women is almost equal.

COPD is characterised by persistent respiratory symptoms and airflow limitation. This is due to airway and/or alveolar abnormalities, usually caused by significant exposure to noxious (harmful) particles or gases. 2

Signs and Symptoms

Common signs and symptoms of COPD include3:

  • Shortness of breath, particularly on exertion

  • Ongoing or chronic cough

  • Regular sputum production

  • Frequent bronchitis/lower respiratory infections

  • Wheezing

Aetiology

Tobacco smoking is a leading cause of COPD. 4 However, incidences of COPD also occur in non- smokers. 5

External risk factors associated with COPD in non-smokers include :

  • Passive smoking (being in close proximity to other smokers)

  • Occupational exposure to substances e.g. coal and silica

  • Noxious fumes and vapours

  • Indoor air pollution from the burning of biomass fuels

  • Outdoor air pollution in urban areas

Internal risk factors include genetic predisposition, damaged airways due to prenatal maternal smoke exposure and childhood respiratory infection. 6

A small percentage of patients with a genetically inherited disorder known as alpha-1 antitrypsin deficiency will develop COPD. It often affects younger individuals, and usually results in the development of emphysema in the lower lobes of the lungs. It can sometimes be associated with bronchiectasis, asthma and liver involvement. 7 8

Diagnosis

A diagnosis of COPD should be considered in patients displaying clinical signs and symptoms. This is especially important for individuals who have experienced prolonged exposure to the external risk factors mentioned above.

Spirometry:

A diagnosis of COPD is confirmed by spirometry tests.

Spirometry is a standard procedure used to measure lung function; specifically, it measures the amount and/or speed of air inhaled and exhaled. 9

A spirometer provides the following readings: 10

  • FEV1: Forced Expiratory Volume in One Second. This is the volume of air exhaled in the first second and is frequently utilized as an index measure of airway obstruction. FEV1 enables the severity of the disease to be classified and the progression of obstructive lung disease to be followed over time

  • FVC: Forced Vital Capacity. This is the amount of air that can be forcibly exhaled from the lungs after taking the deepest breath possible. A reduced FVC value implies restrictive ventilatory defect and serves as an independent and reliable mortality predictor in the human population.

The FEV1/FVC ratio is used in the diagnosis of COPD. A normal ratio is above 0.75-85, though this is age dependent. Values less than 0.70 are suggestive of airflow limitation with an obstructive pattern and results in a diagnosis of COPD. 11

Section 2 Impact of COPD

COPD significantly impacts on the patients themselves12 and the wider healthy economy; in the United Kingdom, COPD costs the NHS around £1.9 billion each year. 13

Specifically, COPD has been associated with anxiety, depression and sleep problems. 17 18

In a 2014 systematic review, depression was a predictor of poor quality of life in people with COPD.19 Depression in COPD patients has also been found to be associated with an increased risk of hospital admission. 20 21

Psychological Impact

COPD is a progressively disabling condition which is associated with impaired health‐related quality of life. 14 15 16

NICE guidelines for depression in adults with a chronic physical health problem such as COPD recommend that healthcare professionals monitor for anxiety and depression amongst patients and signpost them towards relevant treatment services if necessary.

Comorbidities

In addition to respiratory symptoms, physical incapacity and mental health problems, COPD patients often have comorbidities such as: 22

  • Lung cancer

  • Asthma

  • Obstructive sleep apnoea syndrome

  • Hypertension

  • Cardiovascular disease

  • Diabetes

  • Metabolic syndrome

  • Dysfunctional skeletal myopathies

  • Osteoporosis

Impaired health status and health-related quality of life is an independent predictor of hospitalisations and mortality. 23 24

Healthcare professionals working with COPD patients should work together in order to provide a multidisciplinary approach to managing multiple comorbidities.

Nutritional Implications of COPD

The prevalence of obesity amongst the COPD population is 42%. An interesting paradox can be seen in COPD, with overweight and mild obesity (BMI 25-30 kg/m2) being associated with improved survival rate and a slower decline in lung function. 25

On the contrary, the prevalence of disease-related malnutrition amongst the COPD community is estimated to be between 20% and 45%. 26

This article focuses on managing malnutrition in COPD since poor nutritional status is associated with negative outcomes in this patient group.

These may include: 27 28

  • Decreased muscle strength

  • More rapid deterioration in lung function

  • Decrease in exercise capacity

  • Worsening quality of life indices 29

  • Increased length of hospital stay

  • More frequent exacerbations

  • Increased mortality rates

Malnutrition is a significant and independent predictor of mortality in COPD patients, with malnourished patients having a threefold increased risk of dying within a year. 30

Inadequate dietary intake is the most commonly cited reason for malnutrition in COPD patients. 31
32 Poor dietary intake can be affected by many different factors, including loss of appetite, depression and anxiety and physical limitations such as difficulty breathing while eating, problems chewing, taste alterations and coughing. 33

Other causes of malnutrition in COPD include:

  • An imbalance between energy intake and expenditure; it has been demonstrated that resting energy expenditure (REE) is increased in COPD patients 34

  • Systemic inflammation 35

  • Hypoxia (when the blood does not deliver enough oxygen to the air sacs in the lungs)

  • Effect of medications

  • Changes in body composition. 36 Around a third (35%) of COPD patients have a fat free mass

    (FFM) which is significantly lower than normal. 37

Screening for Malnutrition in COPD Patients

BAPEN, the British Association for Parenteral and Enteral Nutrition, recommends routine nutritional screening with a validated screening tool such as the Malnutrition Universal Screening Tool
(MUST) for all COPD patients. 38

This should be done on first contact with a patient and after any changes in condition (such as recent exacerbations or changes in social or psychological status).

Repeat screening should take place at least annually and more frequently if risk of malnutrition is identified.

NICE guidelines recommend that Body Mass Index (BMI) should be calculated in all patients with COPD and that they should be referred to a dietitian for advice if they have a BMI which has changed significantly over time or is outside the range of 20 to 25 kg/m2. 39

NICE also state that special attention must be paid to unintentional weight changes, particularly if the change is more than 3kg in the elderly.

Section 3
Nutritional Strategies for COPD Patients

Identifying and addressing malnutrition in COPD patients can improve nutritional status, clinical outcomes and reduce healthcare costs. 40

If patients are deemed to be ‘at risk of malnutrition’, nutritional goals should be agreed and appropriate steps taken to correct malnutrition and optimise nutritional status.

Dietetic strategies may include provision of dietary information (i.e. food-first advice), special diets (i.e. texture-modified), eating assistance and oral nutrition supplements.

The nutrition advice given should aim to increase intake of all micro- and macronutrients. However, it’s important to note that nutritional requirements (particularly for energy and protein) may vary depending on whether the patient has stable COPD or an acute exacerbation. 41

For patients who have lost weight, a weight gain of 2kg should be used as a therapeutic target as this amount has been associated with a number of functional improvements in COPD patients. 42

Pulmonary rehabilitation is often used in COPD patients and nutrition should be implemented as part of this treatment plan. 43

The Managing Malnutrition in COPD Pathway

“The Managing Malnutrition in COPD Pathway is a practical guide to assist healthcare professionals in identifying and managing people with COPD who are malnourished or at risk of disease-related malnutrition.” (Malnutrition Pathway, 2019)

It is based on clinical evidence alongside accepted best practice and includes guidance to assist in the appropriate use of oral nutritional supplements (ONS).

The pathway recommends a treatment algorithm for COPD patients based on MUST screening tool scores. It is accompanied by a series of colour-coded information booklets for use with patients, which include dietary advice for the three malnutrition risk categories (low risk, medium risk, high risk).

Identifying Malnutrition According to Risk Category Using 'MUST' - First Line Management Pathway

MUST Score 0 Low Risk - routine clinical care

  • Provide green information leaflet: Eating Well For Your Lungs to raise awareness of the importance of a healthy diet

  • If BMI >30 (obese) treat according to local guidelines

  • Review / re-screen annually.

MUST Score 1 Medium Risk - observe

  • Dietary advice to maximise nutritional intake. This includes encouraging small frequent meals and snacks, with high energy and protein food and fluids

  • Provide yellow leaflet: Improving Your Nutrition In COPD to support dietary advice

  • NICE recommends COPD patients with a BMI <20kg/m2 should be prescribed oral nutritional

    supplements (ONS).

  • Review progress after 1-3 months

  • If improving continue until ‘low risk’ - if deteriorating, consider treating as ‘high risk’.

MUST Score 2 + High Risk - treat

  • Dietary advice to maximise nutritional intake. This includes encouraging small frequent meals and snacks, with high energy and protein food and fluids

  • Provide red leaflet: Nutrition Support In COPD to support dietary advice

  • Prescribe oral nutritional supplements (ONS) and monitor

  • Review progress

  • On improvement, consider managing as ‘medium risk’

Oral Nutritional Support and COPD

A growing number of studies supports the use of Oral Nutritional Supplements (ONS) in malnourished patients with COPD.

A Cochrane Review of 17 studies44 found that nutritional supplementation promoted an average weight gain of 1.65 Kg over a 24 week period and improved respiratory muscle strength, walking and quality of life in malnourished COPD patients.

Further systematic reviews and meta-analyses of nutritional support45 found that taking ONS for 8 weeks significantly improved respiratory muscle strength, handgrip strength, weight gain (≥2 kg), exercise performance, and quality of life. 46

The use of ONS in COPD patients whilst in hospital has also been associated with a 22% decreased length of hospital stay, a 13% reduction in hospitalisation costs and a 13% decrease in the probability of readmission within 30 days. 47

Appropriate Usage of ONS

The Managing Malnutrition in COPD Pathway recommends the following for the appropriate use of ONS for patients with a low BMI or at risk of malnutrition:

  • Clinical benefits of ONS are often seen with 300-900kcal/day, typically within 2-3 months of supplementation. 48 49 Prescribe 1-3 ONS bottles/sachets per day in addition to oral intake.

  • Review for compliance and adjust for flavour (if needed) after 6 weeks.

  • Patients may benefit from a low volume, high energy/high protein ONS in addition to dietary

    advice due to symptoms of COPD.

  • If following a pulmonary rehabilitation programme consider increased energy and protein

    requirements

  • Continue ONS for a 12 week duration according to clinical condition/nutritional needs.

  • After 12 weeks, patients should be reviewed. ONS should be reduced and eventually stopped

    if nutritional and weight goals have been met. If goals have not been met, adjust the ONS to

    suit the patient’s requirements

  • Thereafter, patients should be reviewed every 3-6 months or upon change in clinical

    condition

  • Stop ONS prescription if goals of intervention have been met and individual is no longer at

    risk of malnutrition.

Section 4
Further Resources on COPD

  • NICE guidelines for COPD diagnosis and management

  • British Lung Foundation - What is COPD?

  • Managing Malnutrition in COPD Pathway

  • Nursing Times - Nutrition Screening in Patients with COPD

  • COPD Foundation - Nutrition for Someone with COPD

  • Nutritional support and functional capacity in chronic obstructive pulmonary disease: a systematic review and meta-analysis.

  • The influence of deprivation on malnutrition risk in outpatients with chronic obstructive pulmonary disease (COPD).

  • Cochrane Review: Nutritional Supplementation for Stable COPD

  • Nutritional Support in COPD: a systematic review and meta-analysis

References:
1. World Health Organisation . Chronic obstructive pulmonary disease (COPD) . Key Facts
2. Singh et al. (2019) Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease: the GOLD science committee report 2019. Eur Respir J. May 18;53(50)
3. NICE guideline [NG115] Published date: December 2018 Last updated: July 2019 Chronic obstructive pulmonary disease in over

16s: diagnosis and management.
4. Gupta, D et al (2013). Guidelines for diagnosis and management of chronic obstructive pulmonary disease: Joint ICS/NCCP (I) recommendations. Lung India .Jul-Sep; 30(3): 228–267
5. José Luis López‐Campos et al. (2015) Global burden of COPD . Respirology.. Jan;21(1):14-23
6. José Luis López‐Campos et al. (2015) Global burden of COPD . Respirology.. Jan;21(1):14-23
7. Duncan D (2016). Duncan D. Br J Nurs. Apr 14-27;25(7):360, 362-6.
8. Celli, B & Agustí, A. (2018). COPD: time to improve its taxonomy? ERJ Open Res.Jan; 4(1): 00132-2017
9. Ranjan, A et al. (2019).Genetic underpinnings of lung function and COPD. Journal of Genetics 98:76
10. José Luis López‐Campos et al. (2015) Global burden of COPD . Respirology.. Jan;21(1):14-23
11. Ragaišienė, G (2019). Diagnosing COPD in primary care: what has real life practice got to do with guidelines? Multidiscip Respir Med. 14: 28.
12. Miravitlles M et al. (2017) Understanding the impact of symptoms on the burden of COPD.Respir Res. 2017 Apr 21;18(1):67. 13. Trueman, D et al Estimating the economic burden of respiratory illness in the UK report. British Lung Foundation
14. Garrido P. et al.. (2006). Negative impact of chronic obstructive pulmonary disease on the health‐related quality of life of patients. Results of the EPIDEPOC study. Health and Quality of Life Outcomes, 4, 31 10.1186/1477-7525-4-31
15. Jones P. et al (2011). Properties of the COPD assessment test in a cross‐sectional European study. European Respiratory Journal, 38(1), 29–35.
16. Long, H et al. (2019)Does health coaching improve health‐related quality of life and reduce hospital admissions in people with chronic obstructive pulmonary disease? A systematic review and meta‐analysis. Br J Health Psychol. 2019 Sep; 24(3): 515–546
17. Yohannes AM et al. (2014) Depression and anxiety in patients with COPD. Eur Respir Rev. Sep;23(133):345-9.
18. Lal C et al. (2019) Prevalence of self-reported sleep problems amongst adults with obstructive airway disease in the NHANES cohort in the United States. Sleep Breath. Sep 13
19. Blakemore, A et al. (2014) Depression and anxiety predict health-related quality of life in chronic obstructive pulmonary disease: systematic review and meta-analysis. Int J Chron Obstruct Pulmon Dis. 2014; 9: 501–512.
20. Dickens C.et al.. (2012). Does depression predict the use of urgent and unscheduled care by people with long term conditions? A systematic review with meta‐analysis. Journal of Psychosomatic Research, 73, 334–342
21. Guthrie E. A. et al. . (2016). Depression predicts future emergency hospital admissions in primary care patients with chronic physical illness. Journal of Psychosomatic Research, 82, 54–61
22. Hillas, G et al. (2015). Managing comorbidities in COPD Int J Chron Obstruct Pulmon Dis. 2015 Jan 7;10:95-109.
23. Jansen, C et al. (2013). The impact of COPD on health status: findings from the BOLD study.European Respiratory Journal 2013 42: 1472-1483;
24. Almagro P, et al. (2002). Mortality after hospitalization for COPD. Chest 2002; 121: 1441–1448.
25. Mihaltan, Florin, and Anca Hancu. 2019. “OBESITY DILEMMA IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE”. Romanian Journal of Diabetes Nutrition and Metabolic Diseases 26 (1), 7-9.
26. Mete, B et al. (2018) Prevalence of malnutrition in COPD and its relationship with the parameters related to disease severity.Int J Chron Obstruct Pulmon Dis. 2018 Oct 11;13:3307-3312.
27. Long R et al. (2018).Nutritional care in Chronic Obstructive Pulmonary Disease. Br J Community Nurs. Jul 1;23(Sup7):S18-S26. 28. Aniwidyaningsih et al. (2008) Impact of nutritional status on body functioning in chronic obstructive pulmonary disease and how to intervene. Curr Opin Clin Nutr Metab Care.Jul; 11(4): 435–442.
29. Ezzel. L et al. (2000) Malnutrition in chronic obstructive pulmonary disease.Am J Clin Nutr. 2000 Dec;72(6):1415-6.
30. Tzanakis N et al. (2015) Managing comorbidities in COPD. Int J Chron Obstruct Pulmon Dis. ;95:95
31. Laudisio A et al. (2016).Dietary intake of elderly outpatients with chronic obstructive pulmonary disease. Arch Gerontol Geriatr.;64:75–81
32. Nordén J et al (2015) Nutrition impact symptoms and body composition in patients with COPD. Eur J Clin Nutr. Feb;69(2):256-61 33. Nordén J et al (2015) Nutrition impact symptoms and body composition in patients with COPD. Eur J Clin Nutr. Feb;69(2):256-61 34. Hogan D et al (2017). Nutritional status of Vietnamese outpatients with chronic obstructive pulmonary disease. J Hum Nutr Diet. 2017;30(1):83–89
35. Schols AM. (2015). The 2014 ESPEN Arvid Wretlind Lecture: metabolism & nutrition: shifting paradigms in COPD management. Clin Nutr. ;34(6):1074–1079
36. Deutz NEP et al. (2019). The Underappreciated Role of Low Muscle Mass in the Management of Malnutrition. J Am Med Dir Assoc.Jan;20(1):22-27
37. Sang Hun Kim, et al. (2019) Sarcopenia Associated with Chronic Obstructive Pulmonary Disease.J Bone Metab. May; 26(2): 65– 74.
38. Long R et al. (2018).Nutritional care in Chronic Obstructive Pulmonary Disease. Br J Community Nurs. Jul 1;23(Sup7):S18-S26. 39. NICE (2018). Chronic obstructive pulmonary disease in over 16s: diagnosis and management. [NG115]. Accessed online: https://www.nice.org.uk/guidance/NG115 on 16th October 2019.
40. Shepherd A (2010) The nutritional management of COPD: an overview. Br J Nurs. May 13-26;19(9):559-562.
41. Collins P. Weekes CE (2019). Manual of Dietetic Practice. 6th Edition. Wiley-Blackwell.
42. Collins et al (2013)Nutritional support and functional capacity in chronic obstructive pulmonary disease: a systematic review and meta-analysis. Respirology, 18 , pp. 616-629
43. NICE (2018). Chronic obstructive pulmonary disease in over 16s: diagnosis and management. [NG115]. Accessed online: https://www.nice.org.uk/guidance/NG115 on 16th October 2019.
44. Ferreira, I et al. (2012). Nutritional supplementation for stable chronic obstructive pulmonary disease.Cochrane Systematic Review - Intervention Version published: 12 December
45. Collins et al (2013)Nutritional support and functional capacity in chronic obstructive pulmonary disease: a systematic review and meta-analysis. Respirology, 18 , pp. 616-629
46. Collins PF, (2012) Nutritional support in chronic obstructive pulmonary disease: a systematic review and meta-analysis. Am J Clin Nutr. Jun;95(6):1385-95.
47. Snider JT (2015) Effect of hospital use of oral nutritional supplementation on length of stay, hospital cost, and 30-day readmissions among Medicare patients with COPD. Chest. Jun;147(6):1477-1484.
48. Norman K et al (2008) Three month intervention with protein and energy rich supplements improve muscle function and quality of life in malnourished patients with non-neoplastic gastrointestinal disease – a randomized controlled trial. Clin Nutr. Feb; 27(1):48- 56
49. Gariballa et al (2006). A randomized, double-blind, placebo-controlled trial of nutritional supplementation during acute illness. Am J Med 119(8):693-699.